Manchester Capital Management LLC Sells 362 Shares of Becton, Dickinson and Company $BDX

Manchester Capital Management LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,367 shares of the medical instruments supplier’s stock after selling 362 shares during the period. Manchester Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $3,336,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the period. Avantax Advisory Services Inc. lifted its position in Becton, Dickinson and Company by 30.5% during the first quarter. Avantax Advisory Services Inc. now owns 24,219 shares of the medical instruments supplier’s stock valued at $5,548,000 after purchasing an additional 5,659 shares during the period. Cetera Investment Advisers boosted its holdings in Becton, Dickinson and Company by 18.8% in the first quarter. Cetera Investment Advisers now owns 78,838 shares of the medical instruments supplier’s stock worth $18,058,000 after purchasing an additional 12,485 shares during the last quarter. one8zero8 LLC bought a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $202,000. Finally, LPL Financial LLC raised its stake in Becton, Dickinson and Company by 20.2% during the 1st quarter. LPL Financial LLC now owns 358,539 shares of the medical instruments supplier’s stock valued at $82,127,000 after buying an additional 60,253 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,249 shares of company stock valued at $231,358 in the last quarter. 0.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of research reports. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada cut their price target on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research note on Friday, November 7th. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $203.27.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $191.32 on Tuesday. The company has a market capitalization of $54.84 billion, a P/E ratio of 34.41, a P/E/G ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The firm’s 50 day simple moving average is $186.94 and its two-hundred day simple moving average is $182.60. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.